Title:
Development of a Rapid and Sensitive Method for the Isolation and Diagnosis of Microorganisms in Human Blood
Agreement Value:
$259,000.00
Agreement Date:
Jul 1, 2018 - Jan 1, 2020
Description:
“CIIP - Brazil with Genotyping” The aim of this project is to develop a novel method to isolate and detect pathogens causing Blood Stream Infections (BSI). Initially, a sensitive kit will be developed to isolate DNA from all the microorganisms present in blood. Next, panels will be developed to detect the microorganisms that cause over 95% of BSI using real-time PCR and/or NGS, and to screen for antibiotic resistance of these microorganisms.
Organization:
National Research Council Canada
Expected Results:
The Canadian International Innovation Program fosters and supports collaborative industrial research and development projects with high potential for commercialization between Canada and partner countries. It also stimulates bilateral science and technology networking and matchmaking activities to further new partnerships and accelerate the commercialization of research and development.
Location:
Thorold, Ontario, CA L2V 4Y6
Reference Number:
172-2018-2019-Q3-911219
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
870378197
Recipient Type:
For-profit organization
Recipient's Legal Name:
Norgen Biotek Corporation
Federal Riding Name:
Niagara Centre
Federal Riding Number:
35066
Program:
Canadian International Innovation Program
Program Purpose:
The Canadian International Innovation Program fosters and supports collaborative industrial research and development projects with high potential for commercialization between Canada and partner countries. It also stimulates bilateral science and technology networking and matchmaking activities to further new partnerships and accelerate the commercialization of research and development.
Coverage:
The Canadian International Innovation Program supports industrial R & D partnerships and matchmaking activities between Canadian companies and foreign partners with a view to accelerating commercialization and facilitating market access.